Searched for: in-biosketch:true
person:pillim01
SEX DIFFERENCES IN GOUT CHARACTERISTICS: TAILORING CARE FOR WOMEN AND MEN [Meeting Abstract]
Harrold, LR; Etzel, CJ; Gibofsky, A; Kremer, JM; Pillinger, MH; Saag, KG; Schlesinger, N; Terkeltaub, R; Cox, V; Greenberg, JD
ISI:000346919800356
ISSN: 1468-2060
CID: 1598852
Hyperuricemia, Gout, and Related Comorbidities: Cause and Effect on a Two-Way Street
Karis, Elaine; Crittenden, Daria B; Pillinger, Michael H
The prevalence of gout and hyperuricemia has increased dramatically during the last several decades, to the point that gout is the most common inflammatory arthritis in the United States, affecting approximately 8 million Americans. Patients with gout frequently have multiple comorbidities, including hypertension, chronic kidney disease, cardiovascular disease, obesity, diabetes, and hyperlipidemia, all of which have significant adverse impact on public health. In some cases (eg, chronic kidney disease) it is clear that the presence of the comorbidity contributes to the progression of hyperuricemia and/or gout. Conversely, the question of whether gout/hyperuricemia themselves contribute to the pathogenesis of gout comorbidities is an area of intensifying investigation. In vitro and animal models, large epidemiologic studies, and small clinical trials suggest that gout and/or hyperuricemia may contribute to hypertension, chronic kidney disease, and cardiovascular disease. More limited hypothesis-generating studies suggest a potential role for diabetes and obesity. Given that available drugs can lower serum urate levels and manage gout, it would be important to know whether not only gout and/or hyperuricemia can contribute to comorbidities but also better gout/hyperuricemic control can ameliorate some or all of these related conditions. We review the clinical associations between gout and its common comorbid conditions and the evidence supporting a causal relation between them. The evidence that gout and hyperuricemia contribute to the pathogenesis of their comorbidities creates greater urgency for appropriate gout management.
PMID: 24937517
ISSN: 0038-4348
CID: 1036702
The reply [Letter]
Dalvi, Sam R; Pillinger, Michael
PMID: 24262745
ISSN: 0002-9343
CID: 687382
Sex Differences In Gout Evaluation and Management [Meeting Abstract]
Harrold, Leslie R. ; Etzel, Carol ; Gibofsky, Allan ; Kremer, Joel M. ; Pillinger, Michael H. ; Saag, Kenneth G. ; Schlesinger, Naomi ; Terkeltaub, Robert ; Cox, Vanessa ; Greenberg, Jeffrey D.
ISI:000325359203179
ISSN: 0004-3591
CID: 656422
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Results From a Community-Based, Informatics-Driven Retrospective Cohort Study [Meeting Abstract]
Crittenden, Daria B. ; Shah, Binita ; Sedlis, Steven P. ; Swearingen, Christopher J. ; Wagner, Eric S. ; Henry, Yvette M. ; Berger, Peter B. ; Cronstein, Bruce N. ; Pillinger, Michael H.
ISI:000325359204444
ISSN: 0004-3591
CID: 656352
A Rheumatology Objective Structured Clinical Examination Using Challenging Patient Scenarios Shows Trainee Use Of Medical Jargon Correlates Inversely With Patient Perceptions Of Professionalism [Meeting Abstract]
Berman, Jessica ; Aizer, Juliet ; Bass, Anne R. ; Davidson, Anne ; Dwyer, Edward ; Fields, Theodore R. ; Kang, Jane ; Kerr, Leslie ; Krasnokutsky-Samuels, Svetlana ; Lazaro, Deana M. ; Paget, Stephen A. ; Schwartzman-Morris, Julie S. ; Pillinger, Michael H.
ISI:000325359206241
ISSN: 0004-3591
CID: 657142
Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a Gout Patient Encounter Survey [Meeting Abstract]
Hamburger, Max I. ; Pillinger, Michael H. ; Sederman, Robert ; Fernandez, Gary
ISI:000325359202366
ISSN: 0004-3591
CID: 657172
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study [Meeting Abstract]
Crittenden, Daria B. ; Kimmel, Jessica N. ; Pike, Virginia C. ; Diaz, Daniel ; Shah, Avni ; White, Cilian J. ; DeBerardine, Michael ; Kim, Grace ; Shah, Binita ; Swearingen, Christopher J. ; Greenberg, Jeffrey D. ; Sedlis, Steven P. ; Tenner, Craig T. ; Cronstein, Bruce N. ; Pillinger, Michael H.
ISI:000325359203163
ISSN: 0004-3591
CID: 657412
CHRONIC GOUT, CHRONIC TREATMENT [Meeting Abstract]
Pillinger, M.
ISI:000331587901007
ISSN: 0003-4967
CID: 852902
Saturnine gout, redux: a review
Dalvi, Sam R; Pillinger, Michael H
Illicitly distilled beverages (colloquially referred to as moonshine) account for approximately one third of alcohol consumption worldwide. Moonshine is often produced in makeshift distilling units composed of old, repurposed parts, whose component elements can leach into the distillate. Consequently, the resultant beverages may inadvertently contain harmful toxins, one of which is the metal lead. One manifestation of chronic lead toxicity-from moonshine or other forms of chronic lead poisoning-is the rheumatologic entity known as saturnine gout. With the increasing prevalence of gout over the past few decades, physicians should be aware of the association of moonshine consumption or lead toxicity with gouty arthritis. In this article, we present an overview of saturnine gout, beginning with a discussion of lead poisoning in antiquity and tracing its path to modern times. The contribution of lead to human disease and the clinical features of saturnine gout are outlined. After describing the role of lead in renal insufficiency and purine metabolism, we conclude with a discussion of specific strategies to manage this clinically important form of secondary gout.
PMID: 23510947
ISSN: 0002-9343
CID: 301252